EP1917038A4 - Modulation de régulateurs immunés négatifs et applications pour l'immunothérapie - Google Patents

Modulation de régulateurs immunés négatifs et applications pour l'immunothérapie

Info

Publication number
EP1917038A4
EP1917038A4 EP06718772A EP06718772A EP1917038A4 EP 1917038 A4 EP1917038 A4 EP 1917038A4 EP 06718772 A EP06718772 A EP 06718772A EP 06718772 A EP06718772 A EP 06718772A EP 1917038 A4 EP1917038 A4 EP 1917038A4
Authority
EP
European Patent Office
Prior art keywords
immunotropic
immunotherapy
regulators
modulation
negative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06718772A
Other languages
German (de)
English (en)
Other versions
EP1917038A2 (fr
Inventor
Si-Yi Chen
Kevin C Evel-Kabler
Xiaotong Song
Xue F Huang
Andrew Sharabi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2005/022396 external-priority patent/WO2006112869A2/fr
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of EP1917038A2 publication Critical patent/EP1917038A2/fr
Publication of EP1917038A4 publication Critical patent/EP1917038A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
EP06718772A 2005-06-23 2006-01-19 Modulation de régulateurs immunés négatifs et applications pour l'immunothérapie Withdrawn EP1917038A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2005/022396 WO2006112869A2 (fr) 2004-07-19 2005-06-23 Modulation des regulateurs de la signalisation des cytokines et applications en immunotherapie
PCT/US2006/001751 WO2007001487A2 (fr) 2005-06-23 2006-01-19 Modulation de regulateurs immunes negatifs et applications pour l'immunotherapie

Publications (2)

Publication Number Publication Date
EP1917038A2 EP1917038A2 (fr) 2008-05-07
EP1917038A4 true EP1917038A4 (fr) 2010-01-13

Family

ID=37595624

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06718772A Withdrawn EP1917038A4 (fr) 2005-06-23 2006-01-19 Modulation de régulateurs immunés négatifs et applications pour l'immunothérapie

Country Status (6)

Country Link
EP (1) EP1917038A4 (fr)
JP (1) JP2008546775A (fr)
KR (1) KR20080052549A (fr)
AU (1) AU2006262917A1 (fr)
CA (1) CA2613166A1 (fr)
WO (1) WO2007001487A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012175735A1 (fr) * 2011-06-23 2012-12-27 Vib Vzw Inhibiteurs d'a20 pour le traitement d'infections virales respiratoires
CN104830786A (zh) * 2015-05-05 2015-08-12 杨光华 基于her-2/neu抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途
CN116875520B (zh) * 2023-07-12 2024-06-14 吉林农业大学 表达核糖体失活蛋白的乳酸菌及其在抗轮状病毒中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710129A (en) * 1995-02-23 1998-01-20 Ariad Pharmaceuticals, Inc. Inhibitors of SH2-mediated processes
GB9930616D0 (en) * 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
US7045321B2 (en) * 2001-03-01 2006-05-16 Canon Kabushiki Kaisha Polyhydroxyalkanoate containing unit with phenylsulfanyl structure in the side chain, process for its production, charge control agent, toner binder and toner which contain novel polyhydroxyalkanoate, and image-forming method and image-forming apparatus which make use of the toner
US20030171253A1 (en) * 2001-04-19 2003-09-11 Averil Ma Methods and compositions relating to modulation of A20

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LO DAVID ET AL: "Integrating innate and adaptive immunity in the whole animal", IMMUNOLOGICAL REVIEWS, vol. 169, no. 0, June 1999 (1999-06-01), pages 225 - 239, XP002551756, ISSN: 0105-2896 *
SAITOH TATSUYA ET AL: "A20 is a negative regulator of IFN regulatory factor 3 signaling", JOURNAL OF IMMUNOLOGY, vol. 174, no. 3, 1 February 2005 (2005-02-01), pages 1507 - 1512, XP002551755, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
EP1917038A2 (fr) 2008-05-07
JP2008546775A (ja) 2008-12-25
WO2007001487A2 (fr) 2007-01-04
KR20080052549A (ko) 2008-06-11
WO2007001487A3 (fr) 2009-04-23
AU2006262917A1 (en) 2007-01-04
CA2613166A1 (fr) 2007-01-04

Similar Documents

Publication Publication Date Title
EP2194066A4 (fr) Région constante d'anticorps modifié
EP1771786A4 (fr) Multitraitement d'echantillons
EP2121586A4 (fr) Regulation de l'osteopontine
EP2164996A4 (fr) Riboregulateurs et procedes et composition pour l'utilisation de et avec des riboregulateurs
DE602004012969D1 (de) Phenylacetamide und ihre verwendung als glukokinase-modulatoren
EP1937434A4 (fr) Compositions de revetement pour contenants et procedes d'enduction
EP2013701A4 (fr) Désambiguïsation d'entités nommées
EP2069842A4 (fr) Composants d'éclairage et procédés pour les réaliser
EP2193496A4 (fr) Dispositif d'optimisation de l'organisation de réunions
DE60309800D1 (de) Planare optische Wellenleitervorrichtung zur Umwandlung des Modenfeldes und dessen Herstellungsverfahren
DK1653807T3 (da) Anvendelse af dermale mikroorganer
EP1558591A4 (fr) Modulation de l'anxiete par blocage de l'hydrolyse de l'anandamide
EP1736010A4 (fr) Negociation d'interface
DK1587542T3 (da) Anvendelse af anti-CD100-antistoffer
EP2047400A4 (fr) Modèle de sécurité pour l'intégration d'applications et de partenaires commerciaux
CY2013046I1 (el) Καινοτομος χρηση των αντισωματων αντι il-1bhta
EP1904770A4 (fr) Element d'etancheite magnetique hydrodynamique
FR2884170B1 (fr) Utilisation d'une composition a base de siloxane destinee au moulage-demoulage de pneumatiques
EP1901733A4 (fr) Utilisation d'huperzine pour des pathologies
EP1955200A4 (fr) Retardement du lancement d'applications
EP1746141A4 (fr) Composition d' epaississement
EP1899198A4 (fr) Mecanisme de retenue liberable et procede d'utilisation
EP1947933A4 (fr) Système destiné à l'application contrôlée d'herbicides
EP2023938A4 (fr) MODULATION DE L'EXPRESSION DE ChREBP
EP1908480A4 (fr) Regulateur d'interferon- alpha

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071221

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SHARABI, ANDREW BAYLOR COLLEGE OF MEDICINE

Inventor name: SONG, XIAOTONG BAYLOR COLLEGE OF MEDICINE

Inventor name: HUANG, XUE, F.

Inventor name: EVEL-KABLER, KEVIN, C.

Inventor name: CHEN, SI-YI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYLOR COLLEGE OF MEDICINE

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1118701

Country of ref document: HK

R17D Deferred search report published (corrected)

Effective date: 20090423

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 21/04 20060101AFI20090429BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20091210

17Q First examination report despatched

Effective date: 20100401

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130801

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1118701

Country of ref document: HK